Flexible iris-fixated phakic lens in the treatment of moderate to high myopia: refractive, visual and safety results after 5 years

Session Details

Session Title: Phakic IOLs

Session Date/Time: Monday 09/10/2017 | 08:30-10:20

Paper Time: 08:36

Venue: Meeting Center Room I

First Author: : J.Costa PORTUGAL

Co Author(s): :    T. Monteiro   N. Franqueira   F. Faria-Correia   F. Vaz           

Abstract Details

Purpose:

The surgical treatment of moderate to high myopia may involve several strategies, being the implantation of a phakic intraocular lens (IOL) the preferred option in younger patients. The Artiflex® is a model of phakic, flexible, iris-fixated IOL. The aim of this study was to analyze the efficacy and safety of Artiflex® lens implant (Ophtec BV, Groningen, Netherlands) for refractive correction of moderate to high myopia.

Setting:

Ophthalmology Department of Hospital de Braga, Braga, Portugal

Methods:

We analyzed data from 142 eyes of 68 patients undergoing Artiflex® lens implant for high myopia correction, between January 2010 and July 2016. The minimum follow-up time varied between 12 and 60 months and the parameters analyzed were: under corrected visual acuity (UCVA) and best-corrected visual acuity (BCVA); spherical equivalent; subjective refraction spherical and cylindrical; and endothelial cell count. The indexes for efficacy and safety were also calculated.

Results:

At 12 months, we obtained a significant improvement in BCVA, from 0.80±0.19 to 0.92±0.16. 53% of eyes achieved gains of 1 or more lines of BCVA, while 6.9% have lost 1 or more lines of BCVA; spherical equivalent decreased from -9.47D±3.82 to -0.21D±0.47 at 12 months and -1.04D±0.64 at 60 months. At 12 months, 76% of patients achieved a spherical equivalent between ±0.50D and 96% within ±1.0D. We obtained an average loss of endothelial cells of -1.72% at 12 months, -4.31% at 24 months, -5.87% at 36 months, -9.47% at 60 months, equivalent to an average annual loss of -2.36%.

Conclusions:

The phakic intraocular lens Artiflex® is an effective, safe and stable treatment of moderate to high myopia. A careful annual follow-up is mandatory to monitor the density of endothelial cells and other associated rare complications.

Financial Disclosure:

NONE